Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

Challenges in regulating influenza vaccines for children

Lessons need to be drawn from the assessment and licensing of influenza vaccines in previous years

In April 2010, Australia suspended paediatric influenza vaccinations as a result of febrile convulsions associated with seasonal trivalent influenza vaccine (TIV). Epidemiological investigations have established that the increase in febrile reactions was limited to one of three brands of TIV used in Australia that year — CSL Biotherapies Fluvax or Fluvax Junior (CSL TIV), registered as Afluria in the United States and Enzira in the United Kingdom.13 Health authorities in Australia estimated that the risk of febrile convulsions in children aged 6 months to 4 years after vaccination with CSL 2010 TIV ranged from 3–10 per 1000 vaccinated.1,3 This figure is remarkable because TIV has an excellent safety record in children and before 2010 was only rarely associated with febrile convulsions. The largest published population-based study found only one febrile convulsion after TIV vaccination of 45 356 children aged 6–23 months,